Novo Nordisks semaglutide, the GLP-1 analog used in Ozempic and Wegovy, showed an average weight loss of 10.6% at 68 weeks with the 2.4 mg dose in adults with type 2 diabetes and obesity or overweight in the STEP 2 Phase 3 trial
If you are pregnant or plan to become pregnant, talk to your healthcare provider about the best way to control your blood sugar
Retatrutide cannot be used in compounding under federal law
Frequently Asked Questions What is retatrutide used for
Scope of the GLP-1 agonists Market Report The GLP-1 agonists drug market report covers a segment of key events, an executive summary, target patient pool, epidemiology and market forecasts, information around patient journey and varying biomarker testing rates Additionally, an all-inclusive account of the current and emerging therapies drug chapters, insights on Glucagon-like Peptide-1 (GLP-1) Agonists addressable patient pool A detailed review of the Glucagon-like Peptide-1 (GLP-1) Agonists market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report The GLP-1 agonists market report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, and treatment preferences that help in shaping and driving the 7MM Glucagon-like Peptide-1 (GLP-1) Agonists market